During the corresponding time, Bullfrog Ai Holdings Inc recorded a revenue increase by 547.64 % year on year, While revenue at the Bullfrog Ai Holdings Inc 's corporate clients
Bullfrog Ai Holdings Inc's Comment on Sales, Marketing and Customers
The company provides AI and machine learning platforms along with bioinformatics solutions to biotechnology and pharmaceutical companies for drug discovery, target identification, and clinical trial design. It collaborates with companies developing drugs or those with drugs that have failed late Phase II or Phase III trials, offering services across discovery, preclinical, and clinical stages. Its products include bfLEAP™, BullFrog Data Networks™, and bfPREP™, all aimed at biotechnology and pharmaceutical clients. The company has licensed siRNA targeting Beta2-spectrin from George Washington University for treating diseases such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. It has also licensed an improved formulation of Mebendazole from Johns Hopkins University for glioblastoma, which is currently in clinical testing.
Abstract In an era where the pharmaceutical landscape is rapidly evolving, the integration of artificial intelligence (AI) and machine learning into drug development processes has emerged as a pivotal factor in enhancing efficiency and outcomes. This article discusses the groundbreaking strategic collaboration between BullFrog AI and Sygnature Discovery, which aims to leverage proprietary AI-driven data insights to facilitate drug discovery across the global biopharmaceutical sector.The pharmaceutical industry is undergoing a paradigm shift, characterized by the increasing adoption of innovative technologies aimed at improving drug development efficacy. The partnership between BullFrog AI, a prominent player...
In a groundbreaking collaboration, BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has teamed up with the Lieber Institute for Brain Development (LIBD) to make significant strides in the fight against neuropsychiatric disorders. The partnership leverages BullFrog AI s cutting-edge artificial intelligence (AI) and machine learning technology, culminating in the identification of promising new drug targets.Neuropsychiatric disorders, including schizoaffective disorder, bipolar disorder, and major depressive disorder, have long posed significant challenges for both diagnosis and treatment. Current therapeutic options often provide only limited relief and come with a range of side effects that can hinder patien...
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a leading technology-enabled drug development company harnessing the power of artificial intelligence (AI) and machine learning, recently made available the recording of a highly informative and thought-provoking fireside chat. The session, hosted by RedChip Companies on March 5, 2024, featured Vin Singh, CEO of BullFrog AI, and esteemed neuroscientist, Dr. Daniel R. Weinberger, who serves as the Director and CEO of the Lieber Institute for Brain Development (LIBD).During this engaging discussion, the two visionary leaders delved into the potential of AI and its transformative impact on the pharmaceutical and biologics industries. Vin Singh, an industry trail...
Bullfrog Ai Holdings Inc’s Comment on Sales, Marketing and Customers
The company provides AI and machine learning platforms along with bioinformatics solutions to biotechnology and pharmaceutical companies for drug discovery, target identification, and clinical trial design. It collaborates with companies developing drugs or those with drugs that have failed late Phase II or Phase III trials, offering services across discovery, preclinical, and clinical stages. Its products include bfLEAP™, BullFrog Data Networks™, and bfPREP™, all aimed at biotechnology and pharmaceutical clients. The company has licensed siRNA targeting Beta2-spectrin from George Washington University for treating diseases such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. It has also licensed an improved formulation of Mebendazole from Johns Hopkins University for glioblastoma, which is currently in clinical testing.
Sources:
Bullfrog Ai Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bullfrog Ai Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Bullfrog Ai Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
